Pfizer’s COVID-19 Franchise Dominates Best-Seller List
Paxlovid Rose As Cominarty Slowed And Humira Came In Third
Comirnaty was the industry’s top-selling product through the first three quarters of 2022, as in 2021, but Paxlovid proved a fast riser while Comirnaty and Moderna’s Spikevax saw declining sales. Pfizer's two COVID-19 products netted £46bn in total.
